Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 21, 2023

Details for New Drug Application (NDA): 020659

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 020659 describes NORVIR, which is a drug marketed by Abbott, Abbvie, and Abbvie Inc, and is included in five NDAs. It is available from two suppliers. Additional details are available on the NORVIR profile page.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

Summary for 020659

Tradename:	NORVIR
Applicant:	Abbvie
Ingredient:	ritonavir
Patents:	0
Formulation / Manufacturing:	see details

Medical Subject Heading (MeSH) Categories for 020659

Cytochrome P-450 CYP3A Inhibitors
HIV Protease Inhibitors

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;ORAL			Strength	80MG/ML
Approval Date:	Mar 1, 1996	TE:		RLD:	Yes

Expired US Patents for NDA 020659

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Dow

Moodys

Merck

Colorcon

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.